期刊论文详细信息
Journal of Pharmacological Sciences
CC-Chemokine Ligand 2 Facilitates Conditioned Place Preference to Methamphetamine Through the Activation of Dopamine Systems
Hideki Nishiue1  Naoki Wakida1  Fumihiro Saika1  Shiroh Kishioka1  Yuka Kobayashi1  Norikazu Kiguchi1 
[1] Department of Pharmacology, Wakayama Medical University, Japan
关键词: CC-chemokine ligand 2 (CCL2);    monocyte chemoattractant protein-1 (MCP-1);    chemokine;    inflammation;    addiction;   
DOI  :  10.1254/jphs.14032FP
学科分类:药学
来源: Nihon Yakuri Gakkai Henshuubu / Japanese Pharmacological Society
PDF
【 摘 要 】

References(32)Cited-By(3)Methamphetamine addiction is characterized by drug craving caused by stimulation of the reward system. Because neuroinflammation underlies several neurological disorders, we investigated whether CC-chemokine ligand 2 (CCL2) participates in the methamphetamine dependence using mice. Upregulation of CCL2 but not CC-chemokine receptor 2 (CCR2), a dominant receptor for CCL2, mRNA in both the prefrontal cortex (PFC) and nucleus accumbens (NAC) was observed after methamphetamine (3 mg/kg, s.c.) administration. Using immunohistochemistry, high CCL2 protein levels localized to neurons in the PFC and NAC. In the conditioned place preference (CPP) test, methamphetamine (0.3 �? 3 mg/kg, s.c.) induced a CPP, reflecting psychic dependence on methamphetamine, in a dose-dependent manner. The CPP to methamphetamine was attenuated by RS504393 (1 mg/kg, s.c.), a CCR2 antagonist. Moreover, methamphetamine increased phosphorylated tyrosine hydroxylase (pTH) levels in the ventral tegmental area (VTA). Increased levels of pTH in the VTA by methamphetamine was also suppressed by RS504393. Furthermore, intracerebroventricular injection of recombinant CCL2 increased pTH levels in the VTA. Taken together, we demonstrate that activation of dopamine neurons, which enhances reward-system activity, via the CCL2-CCR2 axis plays a crucial role in psychic dependence on methamphetamine. Novel treatments targeting this machinery may be effective for drug addiction.

【 授权许可】

Unknown   

【 预 览 】
附件列表
Files Size Format View
RO201911300331582ZK.pdf 1253KB PDF download
  文献评价指标  
  下载次数:15次 浏览次数:14次